Reaction

Immobile reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 4,294 reports · 99 co-occurring drugs

As of the last recalculation, Immobile appears in 4,294 FAERS reports alongside 99 co-occurring drug terms. The strongest observed disproportionality signal is RISEDRONATE SODIUM (PRR 17.4).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Risedronate Sodium	109	17.4	17.5
Tocilizumab	316	14.4	14.4
Sulfasalazine	184	11.9	11.9
Captopril	23	11.7	11.7
Rasagiline Mesylate	21	9.2	9.2
Candesartan	65	9.0	9.0
Donepezil Hydrochloride	65	8.7	8.7
Leflunomide	169	8.1	8.1
Rotigotine	24	8.1	8.1
Memantine	22	7.8	7.8
Memantine Hydrochloride	22	7.8	7.8
Amantadine	24	7.6	7.6
Hydroxychloroquine	111	7.4	7.4
Carbidopa And Levodopa	70	7.3	7.3
Rivastigmine	27	7.0	7.0
Bisacodyl Suppositories	18	6.8	6.8
Phenobarbital	20	6.7	6.7
Biscodyl	18	6.7	6.7
Pramipexole	21	6.7	6.7
Prednisolone Acetate	14	6.6	6.6
Pimavanserin Tartrate	72	6.4	6.4
Celecoxib	165	6.3	6.3
Bisacodyl	18	6.2	6.2
Torsemide	42	6.2	6.2
Telmisartan	22	6.0	6.0
Golimumab	102	5.9	5.9
Quinine	10	5.7	5.7
Hydroxychloroquine Sulfate	104	5.6	5.7
Haloperidol	28	5.6	5.6
Haloperidol Lactate	28	5.5	5.5
Oxazepam	24	5.4	5.4
Abatacept	143	5.1	5.1
Denosumab	202	5.0	5.0
Tofacitinib	179	4.9	4.9
Desoximetasone	19	4.9	4.9
Dutasteride	8	4.8	4.8
Ocrelizumab	59	4.7	4.7
Niacin	11	4.6	4.6
Methotrexate Sodium	418	4.5	4.5
Epoetin Alfa	11	4.5	4.5
Tofacitinib Citrate	12	4.4	4.4
Dalfampridine	65	4.4	4.4
Palivizumab	14	4.4	4.4
Anakinra	15	4.4	4.4
Methotrexate	348	4.3	4.3
Alendronate Sodium Tablet	16	4.2	4.2
Levodopa	10	4.0	4.0
Lithium Carbonate	14	4.0	4.0
Certolizumab Pegol	94	4.0	4.0
Asenapine Maleate	7	3.9	3.9
Timolol Maleate	8	3.9	3.9
Brexpiprazole	13	3.8	3.8
Ropinirole	12	3.8	3.8
Dolutegravir Sodium	7	3.8	3.8
Guaifenesin	23	3.7	3.7
Pravastatin Sodium	14	3.4	3.4
Baclofen	60	3.4	3.4
Salmeterol Xinafoate	6	3.4	3.4
Paliperidone	16	3.3	3.3
Oxybutynin Chloride	6	3.3	3.3
Bicalutamide	10	3.2	3.2
Etanercept	353	3.0	3.0
Teriflunomide	28	3.0	3.0
Sitagliptin And Metformin Hydrochloride	13	2.9	2.9
Mirabegron	23	2.9	2.9
Risperidone	77	2.8	2.8
Ziprasidone Mesylate	8	2.7	2.7
Glatiramer Acetate	33	2.7	2.7
Fesoterodine Fumarate	6	2.7	2.7
Tiotropium Bromide Inhalation Spray	6	2.6	2.6
Enzalutamide	30	2.5	2.5
Apalutamide	6	2.5	2.5
Interferon Beta-1A	95	2.4	2.4
Brentuximab Vedotin	5	2.4	2.4
Interferon Beta-1B	9	2.3	2.3
Selexipag	12	2.3	2.3
Fentanyl Citrate	8	2.2	2.2
Bosutinib	4	2.2	2.2
Mepolizumab	22	2.2	2.2
Droxidopa	9	2.0	2.0
Alirocumab	10	1.9	1.9
Clozapine	49	1.9	1.9
Gemcitabine	15	1.8	1.8
Romosozumab-Aqqg	5	1.8	1.8
Abiraterone Acetate	15	1.8	1.8
Methoxy Polyethylene Glycol-Epoetin Beta	4	1.8	1.8
Naltrexone Hydrochloride And Bupropion Hydrochloride	3	1.7	1.7
Belimumab	11	1.7	1.7
Paliperidone Palmitate	11	1.7	1.7
Elvitegravir, Cobicistat, Emtricitabine, And Tenofovir Disoproxil Fumarate	3	1.6	1.6
Cariprazine	3	1.6	1.6
Sarilumab	8	1.5	1.5
Leuprolide Acetate	23	1.4	1.4
Trifluridine And Tipiracil	3	1.4	1.4
Hydrocodone Bitartrate And Acetaminophen	15	1.3	1.3
Orlistat	6	1.1	1.1
Valbenazine	5	1.0	1.0
Icodextrin, Sodium Chloride, Sodium Lactate, Calcium Chloride, Magnesium Chloride	5	0.8	0.8
Copper	4	0.4	0.4

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.